Skip to content

Study · Non-randomized trial · n = 12 · 2019

10 results

Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome.

Romero-Ruiz A, Skorupskaite K, Gaytan F, Torres E, Perdices-Lopez C, Mannaerts BM, Qi S, Leon S, Manfredi-Lozano M, Lopez-Rodriguez C, Avendaño MS, Sanchez-Garrido MA and 6 more

Show all authors

Vazquez MJ, Pinilla L, van Duin M, Kohout TA, Anderson RA, Tena-Sempere M

Human reproduction (Oxford, England)1 Dec 2019Cited by 47 (Europe PMC)

PMID31820802 (opens in a new tab)PMCIDPMC6936723 (opens in a new tab)DOI10.1093/humrep/dez205 (opens in a new tab)PepBankPUB-31820802
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In anovulatory women with PCOS, kisspeptin‑54 caused a small rise in LH (P < 0.05).

    In plain wordsIn women with PCOS who do not ovulate, kisspeptin‑54 caused a small rise in luteinising hormone.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseLH rise with KP-54 in women with PCOS
    Study

    n = 12

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    6.4-12.8 nmol/kg · subcutaneous · 21 daysAs given in this study (human).

    Source sentences

    Summary
    In women with PCOS, KP-54 resulted in a small rise in LH (P < 0.05)
    1 context sentence
    Summary · context
    In addition, hormonal (gonadotrophin, estrogen and inhibin B) and ovulatory responses to repeated KP-54 administration, at doses of 6.4-12.8 nmol/kg, s.c. bd for 21 days, were evaluated in a pilot cohort of anovulatory women (N = 12) diagnosed with PCOS, according to the Rotterdam criteria.
  2. 02HumanNon-randomized trialEfficacy outcome

    In anovulatory women with PCOS, kisspeptin‑54 was followed by a rise in serum estradiol (P < 0.05).

    In plain wordsIn women with PCOS who do not ovulate, kisspeptin‑54 was followed by a rise in estradiol.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseSerum estradiol with KP-54 in women with PCOS
    Study

    n = 12

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    6.4-12.8 nmol/kg · subcutaneous · 21 daysAs given in this study (human).

    Source sentences

    Summary
    In women with PCOS, KP-54 resulted in a small rise in LH (P < 0.05), with an equivalent elevation in serum estradiol levels (P < 0.05).
    1 context sentence
    Summary · context
    In addition, hormonal (gonadotrophin, estrogen and inhibin B) and ovulatory responses to repeated KP-54 administration, at doses of 6.4-12.8 nmol/kg, s.c. bd for 21 days, were evaluated in a pilot cohort of anovulatory women (N = 12) diagnosed with PCOS, according to the Rotterdam criteria.
  3. 03HumanNon-randomized trialEfficacy outcome

    In anovulatory women with PCOS, two women had dominant follicle growth with subsequent ovulation and one had follicle growth without ovulation.

    In plain wordsIn women with PCOS who do not ovulate, two women ovulated and one grew a follicle without ovulating after kisspeptin‑54.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    MixedFollicle growth and ovulation in women with PCOS
    Study

    n = 12

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    6.4-12.8 nmol/kg · subcutaneous · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Two women showed growth of a dominant follicle with subsequent ovulation, one woman displayed follicle growth but not ovulation and desensitization was observed in another patient.
    1 context sentence
    Summary · context
    In addition, hormonal (gonadotrophin, estrogen and inhibin B) and ovulatory responses to repeated KP-54 administration, at doses of 6.4-12.8 nmol/kg, s.c. bd for 21 days, were evaluated in a pilot cohort of anovulatory women (N = 12) diagnosed with PCOS, according to the Rotterdam criteria.
  4. 04HumanNon-randomized trialEfficacy outcome

    In anovulatory women with PCOS, no follicular response was detected in the remaining women given kisspeptin‑54.

    In plain wordsIn women with PCOS who do not ovulate, the other women showed no follicle growth after kisspeptin‑54.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changeFollicular response in the other women with PCOS
    Study

    n = 12

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    6.4-12.8 nmol/kg · subcutaneous · 21 daysAs given in this study (human).

    Source sentences

    Summary
    No follicular response was detected in the other women.
    1 context sentence
    Summary · context
    In addition, hormonal (gonadotrophin, estrogen and inhibin B) and ovulatory responses to repeated KP-54 administration, at doses of 6.4-12.8 nmol/kg, s.c. bd for 21 days, were evaluated in a pilot cohort of anovulatory women (N = 12) diagnosed with PCOS, according to the Rotterdam criteria.
  5. 05HumanNon-randomized trialMechanism

    In anovulatory women with PCOS, desensitization to repeated kisspeptin‑54 was observed in one patient.

    In plain wordsIn women with PCOS who do not ovulate, one patient stopped responding to repeated kisspeptin‑54 doses.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableDesensitization to repeated KP-54 in women with PCOS
    Study

    n = 12

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    6.4-12.8 nmol/kg · subcutaneous · 21 daysAs given in this study (human).

    Source sentences

    Summary
    desensitization was observed in another patient.
    1 context sentence
    Summary · context
    In addition, hormonal (gonadotrophin, estrogen and inhibin B) and ovulatory responses to repeated KP-54 administration, at doses of 6.4-12.8 nmol/kg, s.c. bd for 21 days, were evaluated in a pilot cohort of anovulatory women (N = 12) diagnosed with PCOS, according to the Rotterdam criteria.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In anovulatory neonatally androgenized rats, repeated kisspeptin‑54 produced a significant LH response (P < 0.05).

    In plain wordsIn rats with a PCOS-like condition, kisspeptin‑54 raised luteinising hormone.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseLH response to KP-54 in NeNA rats
    Study

    ratn = 10

    Neonatally androgenized (NeNA) rat model of PCOS
    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    100 μg/kg · subcutaneous · 11 daysAs given in this study (rat).

    Source sentences

    Summary
    anovulatory NeNA rats displayed significant LH and FSH responses to KP-54 (P < 0.05)
    1 context sentence
    Summary · context
    At adulthood (postnatal day 100), rats were subjected to daily treatments with a bolus of KP-54 (100 μg/kg, s.c.) or vehicle for 11 days (N = 10 per model and treatment).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In anovulatory neonatally androgenized rats, repeated kisspeptin‑54 produced a significant FSH response (P < 0.05).

    In plain wordsIn rats with a PCOS-like condition, kisspeptin‑54 raised follicle-stimulating hormone.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseFSH response to KP-54 in NeNA rats
    Study

    ratn = 10

    Neonatally androgenized (NeNA) rat model of PCOS
    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    100 μg/kg · subcutaneous · 11 daysAs given in this study (rat).

    Source sentences

    Summary
    anovulatory NeNA rats displayed significant LH and FSH responses to KP-54 (P < 0.05)
    1 context sentence
    Summary · context
    At adulthood (postnatal day 100), rats were subjected to daily treatments with a bolus of KP-54 (100 μg/kg, s.c.) or vehicle for 11 days (N = 10 per model and treatment).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In anovulatory neonatally androgenized rats, kisspeptin‑54 rescued ovulation.

    In plain wordsIn rats with a PCOS-like condition, kisspeptin‑54 restored ovulation.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseOvulation in NeNA rats
    Study

    ratn = 10

    Neonatally androgenized (NeNA) rat model of PCOS
    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    100 μg/kg · subcutaneous · 11 daysAs given in this study (rat).

    Source sentences

    Summary
    anovulatory NeNA rats displayed significant LH and FSH responses to KP-54 (P < 0.05), which rescued ovulation
    1 context sentence
    Summary · context
    At adulthood (postnatal day 100), rats were subjected to daily treatments with a bolus of KP-54 (100 μg/kg, s.c.) or vehicle for 11 days (N = 10 per model and treatment).
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In post-weaning androgenized rats, LH secretion was blunted after repeated kisspeptin‑54 injection.

    In plain wordsIn rats with a PCOS-like condition, the luteinising hormone response weakened after repeated kisspeptin‑54 injections.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseLH secretion after repeated KP-54 in PWA rats
    Study

    ratn = 10

    Post-weaning androgenized (PWA) rat model of PCOS
    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    100 μg/kg · subcutaneous · 11 daysAs given in this study (rat).

    Source sentences

    Summary
    PWA rats showed blunted LH secretion after repeated KP-54 injection and failed to ovulate.
    1 context sentence
    Summary · context
    At adulthood (postnatal day 100), rats were subjected to daily treatments with a bolus of KP-54 (100 μg/kg, s.c.) or vehicle for 11 days (N = 10 per model and treatment).
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In post-weaning androgenized rats, kisspeptin‑54 did not restore ovulation.

    In plain wordsIn rats with a PCOS-like condition, kisspeptin‑54 did not restore ovulation.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changeOvulation in PWA rats
    Study

    ratn = 10

    Post-weaning androgenized (PWA) rat model of PCOS
    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    100 μg/kg · subcutaneous · 11 daysAs given in this study (rat).

    Source sentences

    Summary
    PWA rats showed blunted LH secretion after repeated KP-54 injection and failed to ovulate.
    1 context sentence
    Summary · context
    At adulthood (postnatal day 100), rats were subjected to daily treatments with a bolus of KP-54 (100 μg/kg, s.c.) or vehicle for 11 days (N = 10 per model and treatment).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.